Mylan stumbles in $1.6 billion bid to take over injectables specialist Agila Specialties in India

9 July 2013

US generics and specialty drugs company Mylan (NYSE: MYL) faces a setback in its plan to acquire Indian drugmaker Strides Arcolab’s (BO: 532531) Agila Specialties unit.

Mylan announced the $1.6 billion agreement to buy the firm in February ( The Pharma Letter February 28). But the Economic Times of India is reporting that the Department of Industrial Policy and Promotion (DIPP) is concerned that ownership of critical drug-making facilities are “falling into foreign hands.” The paper said the Foreign Investment Promotion Board (FIPB) deferred a decision on the deal on Friday.

The Business Standard reports that the news has seen Strides Arcolab dip 6% to 790 rand, in an otherwise firm market. The stock of pharmaceutical company has fallen 11% in past three trading sessions on Bombay Stock Exchange (BSE) compared to unchanged value in benchmark Sensex. It added that today the stock opened at 845 rand and hit a low of 783 rand on BSE. A combined 858,858 shares have changed hands on the counter so far on BSE and NSE.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK